Retension Pharmaceuticals
MCLEAN, Virginia, United States · Biopharma, Biotechnology, Healthcare
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patien
Key facts
- Headquarters
- MCLEAN, Virginia, United States
- Employees
- 10
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (RTSN)
- Website
- www.retensionpharmaceuticals.com
- Company page
Recent activity at Retension Pharmaceuticals
- : Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer
- : SEC 8-K (5.02): On October 21, 2026, Retension Pharmaceuticals, Inc. appointed Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026. Mr. Wong brings extensive experience, having held significant roles at companies like The Save Mart Companies and Cytokinetics, Inc. His compensation package includes an annual salary of $360,000, eligibility for a discretionary bonus, a sign-on bonus of $20,000, and a stock option award for 25,000 shares vested over four years. There was no predetermined arrangement for his appointment, ensuring organizational integrity in the hiring process.
- : Retension Pharmaceuticals Appoints LeAnne Bloedon as EVP of Clinical Development
- : Retension Pharmaceuticals Appoints Alison Schecter as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
- : Retension Pharmaceuticals closes $15 million Series B financing to advance RTN-001 for uncontrolled hypertension. The funding supports Phase 2b trials and a new patent issuance.
- : Retension Pharmaceuticals
- : Retension Pharmaceuticals raised $10.4 million in a Series A funding led by undisclosed investors to fund clinical trials for patients suffering from resistant and uncontrolled hypertension.
Retension Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2025 | Series B | $15.0M |
| May 2025 | Venture | $12.3M |
| Aug 2024 | Series A | $10.4M |
Leadership
- Robert Wong, Vice President
- LeAnne Bloedon, Executive Vice President
- Alex Schwartz, Chief Financial Officer
- Alison Schecter, M.D., Chief Medical Officer
- Sabine Bisson, Chief Operating Officer
- Bill Sasiela, Chief Medical Officer
- Eric Keller, Executive Officer
- Donald Olds, Director
- Michael Berendt, Director
Verified email and direct lines for Retension Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Retension Pharmaceuticals in the news
- Retension Pharmaceuticals Announces Formation of Scientific Advisory Board - Business Wire (Sep 14, 2026)
- Retension Pharmaceuticals Announces Pricing of Initial Public Offering - mykxlg.com (Oct 08, 2026)
- Retension Pharmaceuticals Appoints Alison Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer - BioSpace (May 27, 2026)
- Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - The Manila Times (Nov 05, 2026)
- Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs - Business Wire (Sep 10, 2026)
Companies similar to Retension Pharmaceuticals
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Longboard Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Retension Pharmaceuticals: questions and answers
What does Retension Pharmaceuticals do?
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patien
Where is Retension Pharmaceuticals headquartered?
Retension Pharmaceuticals is headquartered in MCLEAN, Virginia, United States.
How many employees does Retension Pharmaceuticals have?
Retension Pharmaceuticals has about 10 employees.
Has Retension Pharmaceuticals raised funding?
Yes. Fundz has recorded 3 funding events for Retension Pharmaceuticals. The most recent, Series B of $15.0M, was in Aug 2025.
Who leads Retension Pharmaceuticals?
Robert Wong is a Vice President at Retension Pharmaceuticals.
What is the latest news on Retension Pharmaceuticals?
On Oct 23, 2026, Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer
Is Retension Pharmaceuticals a public company?
Yes. Retension Pharmaceuticals is publicly traded under the ticker RTSN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy